31 Mar '22
Preliminary safety data suggests lead iNKT agonists, PORT-2 and PORT-3, are well tolerated supporting continued development Company continues to work toward multiple clinical readouts in 2022 Portage is accelerating studies by expanding regions and clinical sites; continued advancement of pipeline
05 Jan '22
WESTPORT, Conn. , Jan. 05, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced
Displaying 11 - 18 of 18